Biospective Inc.
Alex Zijdenbos is an experienced professional in the field of electrical engineering, serving as the Chief Technology Officer at Biospective Inc. since April 2006. Prior to this role, Alex was the NeuGrid Project Leader at Prodema Medical from April 2007 to January 2011 and held various research positions at McGill University from October 1994 to April 2010, including Research Associate and Post-doctoral fellow. Alex's academic journey includes a PhD in Electrical Engineering from Vanderbilt University, completed in 1994, and a Master's degree in Electrical Engineering from Delft University of Technology, which was earned in 1989. Earlier experience includes a tenure as a Research Assistant at Vanderbilt University and a brief student role at Erasmus MC.
This person is not in any teams
This person is not in any offices
Biospective Inc.
1 followers
Biospective Inc. is a specialty Contract Research Organization (CRO) with particular strengths in CNS diseases and disorders, including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, ALS, Schizophrenia, and Depression. Our unique, state-of-the-art technologies and world-class scientific pre-clinical and clinical expertise accelerates the drug discovery timeline. Biospective provides industry-leading services in several cores areas: animal models and behavioral assays; animal imaging (NIGHTWING™ Platform), histology, and quantitative IHC (PERMITS™ Platform); and human MRI, fMRI, PET, and SPECT imaging (PIANO™ Platform). These platforms represent some of Biospective’s fully-automated, unbiased, and high-throughput technologies that provide sponsors with an unparalleled ability to assess the efficacy of their novel therapeutic agents throughout preclinical and clinical drug development.